Molecular Analysis of Gastric and OEsophageal Cancers STudy (MAGnET)

A Prospective Translational Tissue Collection Study in Early and Advanced Gastric and Oesophageal Cancers to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

A prospective translational tissue collection study to identify biomarkers predictive of treatment response/resistance and biomarkers of prognostic value from a series of patients who are investigated for and diagnosed with early or advanced gastric/junctional or oesophageal cancer (oesophagogastric cancer) at The Royal Marsden Hospital.

Study Overview

• Status: Withdrawn
• Conditions: Adenocarcinoma of the Stomach; Adenocarcinoma - GEJ; Adenocarcinoma Esophagus; Squamous Cell Car. - Esophagus
• Intervention / Treatment: Diagnostic test: biopsy

Detailed Description

Tissue samples and biological specimens (which may include blood, stool, saliva) from patients with a suspected/confirmed oesophagogastric cancer (OGC) at The Royal Marsden NHS Foundation Trust over the study period will be collected and stored on behalf of The Royal Marsden NHS Foundation Trust. Molecular analyses including, but not limited to, miRNA analysis, DNA and RNA sequencing, nanostring, RT-PCR and immunohistochemistry will be carried out. Stool and saliva samples may be analysed to assess the microbiota present. Molecular analyses data and microbiota data will be collated in a link-anonymised manner and correlated to clinical outcome data.

This prospective study is intended to set up a database of patients treated both for oesophageal cancer and gastric cancer with availability of annotated clinical data and tumour tissue plus biological specimens. This series will serve as a valuable platform to analyse the expression of several biomarkers of potential interest. There will also be the opportunity to assess the prognostic and predictive role of identified biomarkers in specific patient subgroups and in relation to specific treatments. Within this study, we may also hope to develop organoid and patient derived xenograft models to represent locally advanced and metastatic disease which will support future drug development. We aim to also investigate the microbiome of patients diagnosed with OGC. In addition, this database can serve as a validation cohort for the external validation of findings from other projects in OGC which are of clinical relevance. The molecular analysis plans for the study will develop as the study progresses and as new data emerges which will generate new hypotheses to investigate.

• Study Type: Observational

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SW3 6JJ
    • Royal Marsden NHS Foundation Trust - London

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing endoscopy or surgery for OGC (adenocarcinoma or squamous cell carcinoma) or patients who have recently with been diagnosed with OGC and are due to start treatment. Patients will be recruited from The Royal Marsden NHS Foundation Trust. Patients will need to have sufficient tissue to be available for analysis.

Description

Inclusion Criteria:

1. Patient is being investigated/treated for OGC at The Royal Marsden Hospital during the study period.
2. Patient has an oesophageal/gastric mass or metastasis amenable to core needle biopsy or surgery.
3. Patient is clinically fit enough to undergo a tumour biopsy or surgery (if not already performed) according to investigator assessment and local guidelines.
4. Patient is ≥ 18 years of age.
5. Patient is able to understand the information provided within the patient information sheet and is able to provide written informed consent.
6. Patient has sufficient tissue for analysis.

Exclusion Criteria:

1. Patients who are not treated at The Royal Marsden Hospital or referring centre.
2. Patients who have a second active malignancy other than oesophageal/gastric cancer.
3. Patients who have one or more contraindications to a tumour biopsy or surgery (if not already performed) according to local guidelines.
4. Patients with an uncontrolled concomitant medical condition including, but not limited to, ongoing or active infection not amenable to standard antibiotic therapy, irreversible increased risk of bleeding which prevents biopsy as per standard procedures, or a psychiatric illness or social situation that could affect compliance with study procedures.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
early stage curative disease	Diagnostic test: biopsy; Baseline biopsy and biological specimens
Locally advanced or metastatic disease	Diagnostic test: biopsy; Baseline biopsy and biological specimens

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The prevalence and distribution of biomarkers potentially prognostic or predictive of treatment response/resistance in a large series of patients with OGC	5 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Disease control rate (CR, PR and SD) in locally advanced/metastatic disease	5 years
Duration of response (CR/PR) in locally advanced/metastatic disease	5 years
Progression free survival (PFS) in locally advanced/metastatic disease	5 years
Relapse free survival (RFS) in early stage curative disease	5 years
Overall Survival (OS) according to stage of disease	5 years

Collaborators and Investigators

• Sponsor: Royal Marsden NHS Foundation Trust
• Investigators: Principal Investigator: Dr Avani Athauda, Royal Marsden NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2025
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2030

Study Registration Dates

• First Submitted: February 24, 2022
• First Submitted That Met QC Criteria: November 19, 2024
• First Posted (Actual): November 25, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 3, 2025
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Esophageal Diseases; Carcinoma; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma
• Other Study ID Numbers: CCR 5139; 20/LO/0506 (Other Identifier: REC reference); 264017 (Other Identifier: IRAS project ID)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No